Financials

	2023	2024
Net sales	69.95L 61.44L 57.13L 52.43L 98.51L 67Cr 1Cr 6.78Cr 2.65Cr 33Cr 2.63Cr 2.57Cr 114.5Cr	62.43L 54.83L 50.99L 46.79L 87.92L 60Cr 89.28L 6.06Cr 2.37Cr 30Cr 2.34Cr 2.29Cr 102.2Cr
Net income	-4.52Cr -3.97Cr -3.69Cr -3.39Cr -6.37Cr -435.45Cr -6.47Cr -44Cr -17Cr -214.08Cr -17Cr -17Cr -740.19Cr	-3.28Cr -2.88Cr -2.68Cr -2.46Cr -4.62Cr -315.94Cr -4.69Cr -32Cr -12Cr -155.33Cr -12Cr -12Cr -537.05Cr
Net Debt	1.17Cr 1.02Cr 95.16L 87.32L 1.64Cr 112.2Cr 1.67Cr 11Cr 4.41Cr 55Cr 4.37Cr 4.28Cr 190.72Cr	2.74Cr 2.41Cr 2.24Cr 2.05Cr 3.86Cr 263.72Cr 3.92Cr 27Cr 10Cr 129.66Cr 10Cr 10Cr 448.29Cr

Company Profile

Scorpius Holdings, Inc. is not engaged in any business activities. The Company was previously a contract development and manufacturing organization.

Employees

Sector

Date	Price	Change	Volume
22/26/22	$0.000400	-66.67%	200
21/26/21	$0.001200	-.--%	504
20/26/20	$0.001200	-.--%	8,602
17/26/17	$0.001200	-.--%	246
16/26/16	$0.001200	-.--%	106

Real-time OTC Markets

Market Closed - OTC Markets Other stock markets 07:59:25 03/06/2026 pm IST			5-day change	1st Jan Change
0.001400 ^USD	+7.69%		+16.67%	+600.00%

25/04	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
08/04	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI

Market Cap	12.23T 10.74T 9.99T 9.17T 17.22T 11.78L 17.49T 1L 46.34T 6L 45.9T 44.91T 20.02L	P/E 2023	-0.25x	P/E 2024	-0.03x
Enterprise Value	2.74Cr 2.41Cr 2.24Cr 2.05Cr 3.86Cr 263.84Cr 3.92Cr 27Cr 10Cr 129.71Cr 10Cr 10Cr 448.49Cr	EV / Sales 2023	3.31x	EV / Sales 2024	4.64x
Free-Float	99.97%	Yield 2023 *	-	Yield 2024	-

25/04	Scorpius Holdings, Inc. Announces Board and Committee Changes	CI
08/04	Scorpius Holdings, Inc. Announces Resignation of William Ostrander as Chief Financial Officer, Effective March 31, 2026	CI
11/03	Scorpius Holdings, Inc. announced that it has received $0.031175 million in funding	CI
26/02	Scorpius Holdings, Inc. announced that it has received $0.219544 million in funding	CI
18/02	Scorpius Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
12/02	Scorpius Holdings, Inc. announced that it has received $0.030427 million in funding	CI
13/01	Scorpius Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
16/12	Scorpius Holdings, Inc. announced that it has received $0.044374 million in funding	CI
11/12	Velocity Bioworks, Inc. acquired All of Personal Property and Assets of Scorpius Holdings, Inc. for $16.3 million.	CI
03/12	Scorpius Holdings, Inc. Announces Issuance of Multiple Non-Convertible Promissory Notes with Customary Terms	CI
01/12	Scorpius Holdings, Inc. announced that it has received $0.1541 million in funding	CI
26/11	Scorpius Holdings, Inc. announced that it has received $0.724523 million in funding	CI
25/11	Scorpius Holdings, Inc. announced that it has received $0.03795 million in funding	CI

01/23/01	Brookline Capital Downgrades NightHawk Biosciences to Hold From Buy	MT
03/23/03	Maxim Downgrades NightHawk Biosciences to Hold From Buy	MT
18/22/18	B. Riley Lowers Heat Biologics' PT to $8 from $10, Adjusts Model for Higher Cost of Capital to Support Higher Operating Expenditures Ramp; Keeps Buy Rating	MT
15/22/15	Alliance Global Adjusts Heat Biologics' Price Target to $15.50 From $20, Reiterates Buy Rating	MT
24/22/24	B. Riley Lowers Heat Biologics' Price Target to $10 from $15 After Revising Cost Capital Assumptions, Keeps Buy Rating	MT

13/01	Scorpius : Quarterly Report for Quarter Ending June 30, 2025 (Form 10-Q)	PU
15/24/15	Scorpius : Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability Form 8 K	PU
22/24/22	Scorpius Holdings Announces Partnership with U.S. Biotech Company	AQ
02/24/02	Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats	AQ
30/24/30	Scorpius Holdings Announces Contract with Premier Clinical-Stage Biotech Company; Opens Door to Future GMP Manufacturing Opportunities	AQ

Manager	Title	Age	Since
Jeff Wolf CEO	Chief Executive Officer	63	01/04/2010
Joe Payne COO	Chief Operating Officer	-	-
David Waldman IRC	Investor Relations Contact	-	-

Date	Insider	Type	Main position	Quantity	% Market Cap.
16/05/24	Jeff Wolf	Free	Chief Executive Officer	50,00,000	13.8766%
16/05/24	Seed-One Ventures LLC	Other	Company	0	0%
16/05/24	Orion Holdings LLC	Other	Company	0	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SCORPIUS HOLDINGS, INC.	+7.69%	+16.67%	-97.37%	-100.00%	24.46T
BOXABL INC.	-23.85%	-33.84%	-38.17%	-	1.62TCr
CHURCHILL CAPITAL CORP XI	-5.00%	-6.37%	-	-	80Cr
DEEP FISSION, INC.	-3.84%	-2.38%	-	-	64Cr
CENTIEL AG	+1.22%	+15.73%	+305.64%	-66.22%	65Cr
DRUGS MADE IN AMERICA ACQUISITION II CORP.	+0.10%	+0.10%	-	-	64Cr
CANTOR EQUITY PARTNERS IV, INC.	+0.38%	+0.48%	-	-	60Cr
BAIN CAPITAL GSS INVESTMENT CORP.	+0.16%	+0.05%	-	-	60Cr
AMERICAN EXCEPTIONALISM ACQUISITION CORP. A	+0.52%	-0.85%	-	-	58Cr
Average	-2.50%	-2.31%	+56.70%	-83.11%	230.13Cr
Weighted average by Cap.	-18.89%	-26.06%	-24.85%	-66.23%